NASDAQ · CAI
Healthcare · Biotechnology
$32.10
Up+$0.81 (+2.52%)
Updated Nov 3, 2026, 8:53 PM
SID Score
6.3/10
Composite research score
Smart Money
58/100
Neutral
Price performance · CAI
1M range · 0 trading sessions · Daily adjusted prices
CAI does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
The latest Smart Investors Daily articles mentioning CAI.
Company
Market Activity
Research & News
CAI research
Company profile and research snapshot.
Caris Life Sciences Inc is a patient-centric, next-generation AI TechBio company. It develop and commercialize solutions to transform healthcare through the use of comprehensive molecular information and artificial intelligence/machine learning algorithms at scale.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 27, 2026 | BTIG | Buy | — |
| Oct 19, 2026 | Canaccord Genuity | Hold | — |
| Oct 14, 2026 | JP Morgan | Overweight | — |
| Oct 13, 2026 | TD Cowen | Buy | — |
| Sep 9, 2026 | UBS | Neutral | — |
No generated briefing is available yet.
Yahoo · Oct 29, 2026
Viatris (VTRS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Yahoo · Oct 28, 2026
Caris Life Sciences,?Inc. (CAI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Benzinga · Oct 27, 2026
BTIG analyst Mark Massaro maintains Caris Life Sciences (NASDAQ:CAI) with a Buy and raises the price target from $33 to $38.
Yahoo · Oct 22, 2026
BOSTON, October 22, 2026--Foundation Medicine appoints Chadi Nabhan, M.D., MBA, as chief medical officer.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning CAI.
